Safety and Efficacy of PPP011-kit for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia: a Randomized, Double Blind, Placebo Controlled, Parallel Group Study
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Nabiximols (Primary)
- Indications Cancer pain
- Focus Registrational; Therapeutic Use
- Acronyms SERENITY
- Sponsors Tetra Bio Pharma
- 02 Feb 2021 Planned End Date changed from 30 Oct 2021 to 1 Dec 2023.
- 02 Feb 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Jul 2023.
- 02 Feb 2021 Planned initiation date changed from 1 Jul 2020 to 1 Jul 2022.